Enhanced detection of circulating tumor cells using a MUC1 promoter-driven recombinant adenovirus
In brief, rAdF35-MUC1 emerges as a potent tool for the sensitive and specific identification of CTCs derived from breast cancer patients, holding clinical translation potential for advancing cancer (early) diagnosis, treatment monitoring, and prognosis.
Authors
- Yuan Wan (ORCID: https://orcid.org/0000-0002-0219-5118)
- Jia Cai (ORCID: https://orcid.org/0000-0002-9501-7336)
- Huihui Gu (ORCID: https://orcid.org/0000-0001-6912-7200)
- Chuandong Zhu (ORCID: https://orcid.org/0000-0002-7040-812X)
- Cheng Wang (ORCID: https://orcid.org/0000-0002-0403-1651)
- Qin Zheng (ORCID: https://orcid.org/0000-0002-6624-752X)
- Lixue Wang (ORCID: https://orcid.org/0000-0002-3162-281X)
- Hanfeng Xu
Institutions
- Binghamton University (US)
- Nanjing University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.3389/fonc.2024.1506968
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00